Noble Capital analyst Patrick McCann lowered the firm’s price target on GoHealth (GOCO) to $20 from $25 and keeps an Outperform rating on the shares after the company reported Q2 revenue below the firm’s forecast. The firm now expects Q3 revenue to moderate to $100M, down from its prior estimate, and it trimmed both revenue and adjusted EBITDA estimates for 2025, but it continues to anticipate revenue growth and margin expansion in 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOCO: